• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国 2014 年儿科学会免疫预防指南发布前后,与足月婴儿相比,美国早产儿因呼吸道合胞病毒住院治疗的情况:2012-2016 年。

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016.

机构信息

Division of Neonatal Medicine, Loma Linda University Children's Hospital, Loma Linda, California.

Pediatric Infectious Diseases, Children's Medical Center, NYU Winthrop, Mineola, New York.

出版信息

Am J Perinatol. 2018 Dec;35(14):1433-1442. doi: 10.1055/s-0038-1660466. Epub 2018 Jun 19.

DOI:10.1055/s-0038-1660466
PMID:29920638
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6260117/
Abstract

OBJECTIVE

The objective of this study was to compare risk for respiratory syncytial virus (RSV) hospitalizations (RSVH) for preterm infants 29 to 34 weeks gestational age (wGA) versus term infants before and after 2014 guidance changes for immunoprophylaxis (IP), using data from the 2012 to 2016 RSV seasons.

STUDY DESIGN

Using commercial and Medicaid claims databases, infants born between July 1, 2011 and June 30, 2016 were categorized as preterm or term. RSVH during the RSV season (November-March) were identified for infants aged <6 months and rate ratios (RRs) for hospitalization comparing preterm and term infants were calculated. Difference-in-difference models were fit to evaluate the changes in hospitalization risks in preterm versus term infants from 2012 to 2014 seasons to 2014 to 2016 seasons.

RESULTS

In all seasons, preterm infants had higher RSVH rates than term infants. Seasonal RRs prior to the guidance change for preterm wGA categories versus term infants ranged from 1.6 to 3.4. After the guidance change, the seasonal RRs ranged from 2.6 to 5.6. In 2014 to 2016, the risk associated with prematurity of 29 to 34 wGA versus term was significantly higher than in 2012 to 2014 (<0.0001 for commercial and Medicaid samples).

CONCLUSION

In infants aged <6 months, the risk for RSVH for infants 29 to 34 wGA compared with term infants increased significantly after the RSV IP recommendations became more restrictive.

摘要

目的

本研究旨在比较 29 至 34 孕周(GA)早产儿与足月儿在免疫预防(IP)指南改变前后,2012 至 2016 年 RSV 季节呼吸道合胞病毒(RSV)住院(RSVH)的风险。

研究设计

利用商业和医疗补助数据库,将 2011 年 7 月 1 日至 2016 年 6 月 30 日出生的婴儿分为早产儿或足月儿。确定 <6 月龄婴儿在 RSV 季节(11 月至 3 月)的 RSVH,并计算比较早产儿和足月儿住院率的比值比(RR)。采用差异中的差异模型,评估 2012 至 2014 季节与 2014 至 2016 季节早产儿与足月儿住院风险的变化。

结果

所有季节,早产儿 RSVH 发生率均高于足月儿。指南改变前,早产儿各 GA 类别与足月儿相比,各季节 RR 值范围为 1.6 至 3.4。指南改变后,RR 值范围为 2.6 至 5.6。2014 至 2016 年,29 至 34 GA 早产儿与足月儿相比,早产相关风险明显高于 2012 至 2014 年(商业和医疗补助样本均<0.0001)。

结论

在 <6 月龄婴儿中,与足月儿相比,29 至 34 GA 早产儿 RSVH 的风险在 RSV IP 建议变得更严格后显著增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/715b/6260117/9178d8c6ddf1/10-1055-s-0038-1660466-i180118-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/715b/6260117/9934741ece22/10-1055-s-0038-1660466-i180118-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/715b/6260117/9178d8c6ddf1/10-1055-s-0038-1660466-i180118-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/715b/6260117/9934741ece22/10-1055-s-0038-1660466-i180118-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/715b/6260117/9178d8c6ddf1/10-1055-s-0038-1660466-i180118-2.jpg

相似文献

1
Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016.美国 2014 年儿科学会免疫预防指南发布前后,与足月婴儿相比,美国早产儿因呼吸道合胞病毒住院治疗的情况:2012-2016 年。
Am J Perinatol. 2018 Dec;35(14):1433-1442. doi: 10.1055/s-0038-1660466. Epub 2018 Jun 19.
2
The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.2014年美国儿科学会呼吸道合胞病毒免疫预防指南对美国出生的早产儿的2014 - 2015年全国影响
Am J Perinatol. 2018 Jan;35(2):192-200. doi: 10.1055/s-0037-1606352. Epub 2017 Sep 7.
3
Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.2014 年美国儿科学会免疫预防政策对早产儿因呼吸道合胞病毒住院率、严重程度和费用的影响。
Am J Perinatol. 2020 Jan;37(2):174-183. doi: 10.1055/s-0039-1694008. Epub 2019 Aug 20.
4
Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.早产儿(出生时胎龄为 29-34 周)如未接受门诊帕利珠单抗治疗,其与呼吸道合胞病毒相关住院风险与胎龄相关。
Hum Vaccin Immunother. 2023 Aug;19(2):2252289. doi: 10.1080/21645515.2023.2252289. Epub 2023 Oct 12.
5
Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.2011 - 2017年美国儿科学会免疫预防政策前后美国早产和足月婴儿呼吸道合胞病毒住院情况的最新报告
Hum Vaccin Immunother. 2021 May 4;17(5):1536-1545. doi: 10.1080/21645515.2020.1822134. Epub 2020 Oct 22.
6
Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.早产儿呼吸道合胞病毒(RSV)住院率上升:十年数据。
Am J Perinatol. 2023 Oct;40(14):1529-1536. doi: 10.1055/s-0041-1736581. Epub 2021 Oct 26.
7
SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.SENTINEL1:未接受免疫预防的 29 至 35 孕周出生美国婴儿呼吸道合胞病毒住院的两季研究。
Am J Perinatol. 2020 Mar;37(4):421-429. doi: 10.1055/s-0039-1681014. Epub 2019 Apr 16.
8
RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.2003年至2020年极早产儿(出生孕周<29周)中与呼吸道合胞病毒相关的住院治疗及帕利珠单抗门诊使用情况
Hum Vaccin Immunother. 2022 Nov 30;18(6):2140533. doi: 10.1080/21645515.2022.2140533. Epub 2022 Nov 22.
9
SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.哨兵1:对美国29至35周胎龄且未接受免疫预防的婴儿因呼吸道合胞病毒住院情况的观察性研究。
Am J Perinatol. 2017 Jan;34(1):51-61. doi: 10.1055/s-0036-1584147. Epub 2016 May 27.
10
Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.呼吸道合胞病毒感染对足月儿和早产儿住院治疗的结局及费用影响
J Perinatol. 2016 Nov;36(11):990-996. doi: 10.1038/jp.2016.113. Epub 2016 Aug 4.

引用本文的文献

1
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.帕利珠单抗预防儿童严重呼吸道合胞病毒(RSV)感染。
Cochrane Database Syst Rev. 2025 Jul 23;7(7):CD013757. doi: 10.1002/14651858.CD013757.pub3.
2
Impact of Palivizumab in Preventing Severe Acute Lower Respiratory Infection in Moderate-to-Late Preterm Infants: A Nationwide Cohort Study.帕利珠单抗对中晚期早产儿预防严重急性下呼吸道感染的影响:一项全国性队列研究。
J Korean Med Sci. 2024 Nov 11;39(43):e279. doi: 10.3346/jkms.2024.39.e279.
3
Economic Burden of Medically Attended Respiratory Syncytial Virus Infections Among Privately Insured Children Under 5 Years of Age in the USA.

本文引用的文献

1
Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants.医疗补助计划和商业保险覆盖的婴儿中使用帕利珠单抗进行门诊呼吸道合胞病毒预防的利用趋势。
Infect Dis Ther. 2018 Mar;7(1):121-134. doi: 10.1007/s40121-017-0178-6. Epub 2017 Nov 17.
2
The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.2014年美国儿科学会呼吸道合胞病毒免疫预防指南对美国出生的早产儿的2014 - 2015年全国影响
Am J Perinatol. 2018 Jan;35(2):192-200. doi: 10.1055/s-0037-1606352. Epub 2017 Sep 7.
3
美国 5 岁以下私人医疗保险儿童呼吸道合胞病毒感染的医疗负担。
Influenza Other Respir Viruses. 2024 Jul;18(7):e13347. doi: 10.1111/irv.13347.
4
Model correction of diagnostic coding-based RSV incidence for children 0-4 years in the US.基于诊断编码的美国 0-4 岁儿童 RSV 发病率模型校正。
BMC Infect Dis. 2024 Jun 21;24(1):617. doi: 10.1186/s12879-024-09474-y.
5
Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.早产儿(出生时胎龄为 29-34 周)如未接受门诊帕利珠单抗治疗,其与呼吸道合胞病毒相关住院风险与胎龄相关。
Hum Vaccin Immunother. 2023 Aug;19(2):2252289. doi: 10.1080/21645515.2023.2252289. Epub 2023 Oct 12.
6
Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.帕利珠单抗预防呼吸道合胞病毒引起的严重下呼吸道感染的有效性和安全性:系统评价。
Am J Perinatol. 2024 May;41(S 01):e1107-e1115. doi: 10.1055/a-1990-2633. Epub 2022 Nov 30.
7
RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.2003年至2020年极早产儿(出生孕周<29周)中与呼吸道合胞病毒相关的住院治疗及帕利珠单抗门诊使用情况
Hum Vaccin Immunother. 2022 Nov 30;18(6):2140533. doi: 10.1080/21645515.2022.2140533. Epub 2022 Nov 22.
8
A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year.一项关于美国 1 岁以下婴儿呼吸道合胞病毒负担和医疗保健利用的系统文献综述。
J Infect Dis. 2022 Aug 15;226(Suppl 2):S195-S212. doi: 10.1093/infdis/jiac201.
9
Cost of Respiratory Syncytial Virus Infections in US Infants: Systematic Literature Review and Analysis.美国婴儿呼吸道合胞病毒感染的成本:系统文献回顾与分析。
J Infect Dis. 2022 Aug 15;226(Suppl 2):S225-S235. doi: 10.1093/infdis/jiac172.
10
Cost Savings Without Increased Risk of Respiratory Hospitalization for Preterm Children after the 2014 Palivizumab Policy Update.2014 年帕利珠单抗政策更新后,未增加早产儿呼吸住院风险的成本节约。
Am J Perinatol. 2024 May;41(S 01):e133-e141. doi: 10.1055/a-1845-2184. Epub 2022 May 6.
Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis.
帕利珠单抗在高危婴幼儿中的有效性:倾向评分加权回归分析
Pediatr Infect Dis J. 2017 Aug;36(8):699-704. doi: 10.1097/INF.0000000000001533.
4
Impact of the 2014 American Academy of Pediatrics guidance on respiratory syncytial virus and bronchiolitis hospitalization rates for infants born prematurely.2014年美国儿科学会指南对早产婴儿呼吸道合胞病毒及细支气管炎住院率的影响
J Pediatr. 2017 Jun;185:250. doi: 10.1016/j.jpeds.2017.01.054. Epub 2017 Feb 22.
5
Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections.检测基于指南的帕利珠单抗给药与呼吸道合胞病毒感染住院之间关联的统计功效
Pediatr Infect Dis J. 2017 Mar;36(3):348. doi: 10.1097/INF.0000000000001432.
6
Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus.呼吸道合胞病毒感染高危婴儿的经济负担与健康负担评估
Adv Neonatal Care. 2017 Aug;17(4):292-298. doi: 10.1097/ANC.0000000000000367.
7
Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.孕32至35周出生的美国早产儿的年龄及幼儿接触情况对呼吸道合胞病毒疾病的影响
PLoS One. 2016 Nov 29;11(11):e0166226. doi: 10.1371/journal.pone.0166226. eCollection 2016.
8
Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.帕利珠单抗预防呼吸道合胞病毒感染更新指南的影响:单中心经验
J Pediatr. 2017 Feb;181:183-188.e1. doi: 10.1016/j.jpeds.2016.10.074. Epub 2016 Nov 15.
9
Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.呼吸道合胞病毒感染对足月儿和早产儿住院治疗的结局及费用影响
J Perinatol. 2016 Nov;36(11):990-996. doi: 10.1038/jp.2016.113. Epub 2016 Aug 4.
10
SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.哨兵1:对美国29至35周胎龄且未接受免疫预防的婴儿因呼吸道合胞病毒住院情况的观察性研究。
Am J Perinatol. 2017 Jan;34(1):51-61. doi: 10.1055/s-0036-1584147. Epub 2016 May 27.